Eidos Therapeutics, a BridgeBio company
Open enrollment across a mixed-phase pipeline
According to ClinicalTrials.gov-derived indexes, Eidos Therapeutics, a BridgeBio company sits in the upper quartile of US sponsors by registered trial count (#2,085 of 15,742 sponsors by registered trial count).
Eidos Therapeutics, a BridgeBio company: 6 sponsored US clinical trials, 1 recruiting.
Eidos Therapeutics, a BridgeBio company sponsors 6 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 3 completed. 3 of these trials are in Phase 3-4 (later-stage) and 3 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Amyloid Cardiomyopathy, with 2 trials.
Upper-quartile sponsor footprint
Eidos Therapeutics, a BridgeBio company sits in the upper quartile of the sponsor corpus (#2,085 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Open and recent trials
6 total, page 1 of 1
Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant
NCT06563895
Open-Label Safety Study of Acoramidis (AG10) in Symptomatic ATTR Participants
NCT04988386
Open-Label Study of AG10 in Patients with Cardiomyopathy
NCT03536767
Efficacy and Safety of AG10 in Subjects With Transthyretin Amyloid Cardiomyopathy
NCT03860935
Study of AG10 in Amyloid Cardiomyopathy
NCT03458130
Single and Multiple Ascending Dose Study Assessing the Safety, Tolerability, PK and PD of AG10
NCT03294707
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
| Phase 2 | 2 |
| Phase 3 | 3 |
What is open in the Eidos Therapeutics, a BridgeBio company pipeline
1 recruiting of 6 indexed (17% open); 3 completed (50%).
Phase mix: 3 late (III/IV) vs 3 early (I/II) (balanced across stages).
Top condition: Amyloid Cardiomyopathy (2 trials), 8 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Eidos Therapeutics, a BridgeBio company: open-pipeline peers nationwide
Peers matched on 6 registered trials and 17% open enrollment, not the therapeutic-area sidebar.
Eidos Therapeutics, a BridgeBio company sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 6 trials (± recruiting share)
- 23andMe · 6 trials · 0% recruiting
- Aardvark Therapeutics · 6 trials · 0% recruiting
- Abbisko Therapeutics Co · 6 trials · 67% recruiting
- AbGenomics B.V Taiwan Branch · 6 trials · 0% recruiting
Sponsors near 17% open enrollment (± trial volume)
- Adagene · 17% recruiting · 6 trials
- Agendia · 17% recruiting · 6 trials
- Akamis Bio · 17% recruiting · 6 trials
- Angiodynamics · 17% recruiting · 12 trials
Related
What to do with this Eidos Therapeutics, a BridgeBio company page
6 registered trials is a research-attention snapshot, not an endorsement of Eidos Therapeutics, a BridgeBio company or any single study.
- 1 of Eidos Therapeutics, a BridgeBio company's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Amyloid Cardiomyopathy is the condition Eidos Therapeutics, a BridgeBio company studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Amyloid Cardiomyopathy trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Eidos Therapeutics, a BridgeBio company pipeline card: 6 registered trials from official public datasets.Report a data error.